LIVERSTAT first-line screening tool: MAFLD patients outperformed standard-of-care FIB-4 (training/validation)
LIVERSTAT first-line screening tool: MAFLD patients outperformed standard-of-care FIB-4 (training/validation)
Recommended Clinical Care Pathway with FIB-4 underestimates the prevalence of Advanced Fibrosis, compared to sequential CCP with LIVERSTAT and LSM (NHANES)
Recommended Clinical Care Pathway with FIB-4 underestimates the prevalence of Advanced Fibrosis, compared to sequential CCP with LIVERSTAT and LSM (NHANES)
LIVERSTAT as NIT for risk stratification for MAFLD — a single-centre study using liver biopsy as reference standard (Malaysia)
LIVERSTAT as NIT for risk stratification for MAFLD — a single-centre study using liver biopsy as reference standard (Malaysia)
Fasting vs non-fasting: assessment of the impact on LIVERSTAT
Fasting vs non-fasting: assessment of the impact on LIVERSTAT
LIVERFASt-LFS NIT for Fatty Liver Disease, for Primary Care Provider (PCP) screening
LIVERFASt-LFS NIT for Fatty Liver Disease, for Primary Care Provider (PCP) screening
Assessment of Fatty Liver Disease using LIVERFASt in South-East Asia (real-world evidence)
Assessment of Fatty Liver Disease using LIVERFASt in South-East Asia (real-world evidence)
Comparative Performances of LIVERFASt, Fibroscan and other NITs for severe fibrosis in NAFLD patients (Bordeaux cohort)
Comparative Performances of LIVERFASt, Fibroscan and other NITs for severe fibrosis in NAFLD patients (Bordeaux cohort)
Simulating clinical confidence intervals for black-box algorithmic predictions of liver steatosis
Simulating clinical confidence intervals for black-box algorithmic predictions of liver steatosis
Comparison analysis of FIB-4, LIVERFASt, LSM in Sequential and Combinatory Pathways for NAFLD
Comparison analysis of FIB-4, LIVERFASt, LSM in Sequential and Combinatory Pathways for NAFLD
Long-term prognosis of MAFLD patients according to non-invasive methods
Long-term prognosis of MAFLD patients according to non-invasive methods